February 19, 2024Blood Cancer JournalOpen Access

Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial

View Full Paper

Ask AI

Bookmark

Authors

ÉBÉolia BrissotInserm MLMyriam LabopinInserm HLHélène LabussièreHospices Civils de Lyon

Discussion

Member takes

Implication

Randomized trial finds similar survival between post-transplant cyclophosphamide and anti-thymocyte globulin in stem cell recipients, highlighting cyclophosphamide as an effective alternative.

Key Points

Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide achieves comparable survival to anti-thymocyte globulin after reduced-intensity transplantation.
Disease-free survival reached 65.9% with cyclophosphamide and 67.6% with anti-thymocyte globulin, while overall survival and non-relapse mortality rates remained similar.
Randomized, open-label, multicenter, phase 2 trial evaluates fludarabine and busulfan conditioning, supporting cyclophosphamide for graft-versus-host disease prophylaxis.

Cite This Study

Brissot et al. (2024) studied this question.

synapsesocial.com/papers/68e78822b6db6435876fb0bc https://doi.org/10.1038/s41408-024-00990-3

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial finds similar survival between post-transplant cyclophosphamide and anti-thymocyte globulin in stem cell recipients, highlighting cyclophosphamide as an effective alternative.

Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider